Search
for
Sort by
Research 31–60 of 355
- Skin toxicity caused by EGFR antagonists—An autoinflammatory condition triggered by deregulated IL‐1 signaling?
- Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging
- 1030 EGFR protects the upper hair follicle from staphylococcus driven folliculitis
- The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma
- Supportive Oncodermatology: Addressing dermatologic adverse events associated with oncologic therapies
- Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases
- Acne and acneiform eruptions
- Drug eruptions in dermatology
- PA11 A rare case of a severe papulopustular dermatosis secondary to a germline <i>EGFR</i> mutation
- Distinctive Acne Entities
- Drug-induced acne
- Dermatologic Reactions to Targeted Therapy
- Chemotherapy and Cutaneous Drug Reactions
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Chemotherapy and the Skin: Understanding Dermatologic Side Effects
- Demodicosis and rosacea: Epidemiology and significance in daily dermatologic practice
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Delayed granulomatous eruption of the nose associated with ruxolitinib
- Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
- Rosacea and Rosacea-like Demodicldosis
- Non‐infective mucocutaneous presentations of human immunodeficiency virus infection
- Cutaneous drug reactions
- Sorafenib-Associated Facial Acneiform Eruption
- Acne
- “PRIDE” Complex
- Difficult and rare forms of acne
- Demodex mites
- Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies